Physician profile
Deepali Gupta
NPI 1689802464
$4,756.16
in general payments reported to CMS, 2019-2025
19 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $85.76 · 2021: $1,760 · 2022: $467 · 2023: $662 · 2024: $883 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,092.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,470.01 | 2021 | |
| Abbvie INC. | $1,014.24 | 2021-2025 | |
| Pfizer INC. | $725.47 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $420.67 | 2019-2024 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $399.09 | 2019-2024 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $122.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $109.20 | 2019-2021 | |
| Boston Scientific Corporation | $102.66 | 2019-2025 | Axonics, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $75.18 | 2022 | |
| Amgen INC. | $71.96 | 2019-2021 | |
| Allergan, INC. | $56.06 | 2019-2022 | |
| Si-Bone, INC. | $32.50 | 2024 | |
| Nevro Corp. | $29.68 | 2019 | |
| Collegium Pharmaceutical, INC. | $29.63 | 2023-2024 | Xtampza |
| Bioventus LLC | $26.76 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $24.47 | 2024 | Nalu Neurostimulation System |
| Supernus Pharmaceuticals, INC. | $16.40 | 2021 | |
| Merz Pharmaceuticals, LLC | $14.96 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.67 | 2023 | Exparel, Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.